Clifford Sosin Acquires 28,123 Shares of Cardlytics Inc (NASDAQ:CDLX) Stock

Cardlytics Inc (NASDAQ:CDLX) major shareholder Clifford Sosin bought 28,123 shares of the company’s stock in a transaction dated Monday, October 21st. The shares were purchased at an average cost of $37.45 per share, with a total value of $1,053,206.35. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Clifford Sosin also recently made the following trade(s):

  • On Friday, October 18th, Clifford Sosin bought 16,106 shares of Cardlytics stock. The shares were purchased at an average cost of $37.34 per share, with a total value of $601,398.04.
  • On Wednesday, October 16th, Clifford Sosin bought 9,490 shares of Cardlytics stock. The shares were purchased at an average cost of $37.95 per share, with a total value of $360,145.50.
  • On Monday, October 14th, Clifford Sosin bought 68,252 shares of Cardlytics stock. The shares were purchased at an average cost of $38.85 per share, with a total value of $2,651,590.20.
  • On Monday, October 7th, Clifford Sosin purchased 40,000 shares of Cardlytics stock. The stock was bought at an average price of $35.38 per share, for a total transaction of $1,415,200.00.
  • On Wednesday, October 9th, Clifford Sosin purchased 73,578 shares of Cardlytics stock. The stock was bought at an average price of $34.78 per share, for a total transaction of $2,559,042.84.

CDLX traded up $0.21 during trading on Thursday, hitting $37.27. The company’s stock had a trading volume of 2,564 shares, compared to its average volume of 386,611. Cardlytics Inc has a twelve month low of $9.80 and a twelve month high of $39.83. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.79. The stock’s fifty day moving average price is $35.66 and its 200-day moving average price is $27.49. The firm has a market capitalization of $846.45 million, a P/E ratio of -17.32 and a beta of 1.49.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The firm had revenue of $48.73 million for the quarter, compared to analyst estimates of $43.77 million. During the same period in the previous year, the firm earned ($0.21) earnings per share. The company’s revenue was up 37.0% compared to the same quarter last year. Equities research analysts expect that Cardlytics Inc will post -1.08 EPS for the current fiscal year.

A number of research analysts recently commented on the company. JPMorgan Chase & Co. set a $43.00 price target on Cardlytics and gave the stock a “buy” rating in a research report on Friday, August 9th. Bank of America reaffirmed a “buy” rating and issued a $32.00 price objective (up from $22.00) on shares of Cardlytics in a research note on Wednesday, July 24th. ValuEngine lowered Cardlytics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. SunTrust Banks lifted their price objective on Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Zacks Investment Research raised Cardlytics from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $34.86.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can lifted its position in Cardlytics by 16,371.4% during the 2nd quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after purchasing an additional 1,146 shares during the period. Oppenheimer Asset Management Inc. bought a new position in shares of Cardlytics during the 2nd quarter worth approximately $60,000. Rockefeller Capital Management L.P. bought a new position in shares of Cardlytics during the 2nd quarter worth approximately $85,000. Acadian Asset Management LLC bought a new position in shares of Cardlytics during the 2nd quarter worth approximately $161,000. Finally, Royal Bank of Canada grew its stake in shares of Cardlytics by 166.5% during the 2nd quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock worth $276,000 after acquiring an additional 6,649 shares in the last quarter. 84.08% of the stock is currently owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Story: What is Depreciation?

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.